Navigation Links
Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb
Date:10/18/2010

BEND, Ore., Oct. 18 /PRNewswire/ -- Bend Research Inc. (www.bendres.com), a leading independent technology-based drug-formulation development and manufacturing organization, announced today it has extended its drug discovery enablement and development services agreement with Bristol-Myers Squibb Company (www.bms.com) (NYSE: BMY), a global biopharmaceutical company.

Under the terms of the 3-year agreement, Bristol-Myers Squibb will use Bend Research's formulation development and manufacturing services for preclinical and clinical development. Bend Research will also manufacture drug product intermediates and drug products in its current Good Manufacturing Practice (cGMP) facility for Bristol-Myers Squibb clinical trials.

In the collaboration, the two companies will use their complementary fundamental scientific capabilities to solve complex formulation and process-development challenges.

"We are very excited to extend our working agreement with Bristol-Myers Squibb and to combine the knowledge and experience of our two companies," said Rod Ray, Bend Research CEO. "We share a commitment to applying fundamental science and engineering to the delivery of new medicines that will enhance patients' lives. We look forward to a long and successful relationship."

As part of the collaboration, Bend Research is making its proprietary spray-dried dispersion (SDD) technology available to Bristol-Myers Squibb. This technology has been successfully applied to hundreds of compounds at various phases of development, from preclinical studies to Phase 3 clinical trials.

Since late 2008, Bend Research has rapidly expanded its roster of clients by making its multidisciplinary approach available to companies trying to solve difficult formulation and development problems. The company's flexible client-focused business model and collaborative approach results in long-term alliances that are focused on value creation. Major pharmaceutical companies, mid-sized pharmaceutical companies, and biotech firms around the globe have benefited from Bend Research's innovations and expertise.

About Bend Research Inc.

Bend Research has teamed with clients to solve their most difficult scientific and technical problems for more than 30 years. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies. The firm's innovative drug-delivery solutions grow from a solid base of scientific and engineering fundamental understanding. Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception to commercialization. Bend Research has more than 175 employees based in four state-of-the-art facilities in Bend, Oregon, USA.

For more information about Bend Research and its formulation and manufacturing capabilities, please email or call Dana Settell at Bend Research at Dana.Settell@bendres.com or 541-382-4100.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
2. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
3. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
4. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
5. CVS Caremark Research Highlights How Innovative Plan Designs Help Clients Reduce Drug Spend and Improve Generic Dispensing Rates
6. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
7. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
8. Cellectis bioresearch Announces Establishment of Subsidiary in the US
9. Vaccine and Medication Safety are Parents Top Research Priorities
10. VNSNY Uses Advanced Technology to Assess In-Home Performance of Nurses and Incorporate New Medical Research to Improve Patient Care
11. Varian Medical Systems and Stanford University Win $3.6 Million Five-Year NIH/NCI Research Grant to Develop Advanced Imaging Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):